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Abstract
Background: 10-valent conjugate pneumococcal vaccine/PCV10 was introduced in the Brazilian National Immunization
Program along the year of 2010. We assessed the direct effectiveness of PCV10 vaccination in preventing nasopharyngeal/
NP pneumococcal carriage in infants.
Methods: A cross-sectional population-based household survey was conducted in Goiania Brazil, from December/2010-
February/2011 targeting children aged 7–11 m and 15–18 m. Participants were selected using a systematic sampling. NP
swabs, demographic data, and vaccination status were collected from 1,287 children during home visits. Main outcome and
exposure of interest were PCV10 vaccine-type carriage and dosing schedules (3p+0, 2p+0, and one catch-up dose),
respectively. Pneumococcal carriage was defined by a positive culture and serotyping was performed by Quellung reaction.
Rate ratio/RR was calculated as the ratio between the prevalence of vaccine-types carriage in children exposed to different
schedules and unvaccinated for PCV10. Adjusted RR was estimated using Poisson regression. PCV10 effectiveness/VE on
vaccine-type carriage was calculated as 1-RR*100.
Results: The prevalence of pneumococcal carriage was 41.0% (95%CI: 38.4–43.7). Serotypes covered by PCV10 and PCV13
were 35.2% and 53.0%, respectively. Vaccine serotypes 6B (11.6%), 23F (7.8%), 14 (6.8%), and 19F (6.6%) were the most
frequently observed. After adjusted for confounders, children who had received 2p+0 or 3p+0 dosing schedule presented a
significant reduction in pneumococcal vaccine-type carriage, with PCV10 VE equal to 35.9% (95%CI: 4.2–57.1; p= 0.030) and
44.0% (95%CI: 14.–63.5; p= 0.008), respectively, when compared with unvaccinated children. For children who received one
catch-up dose, no significant VE was detected (p= 0.905).
Conclusion: PCV10 was associated with high protection against vaccine-type carriage with 2p+0 and 3p+0 doses for
children vaccinated before the second semester of life. The continuous evaluation of carriage serotypes distribution is likely
to be useful for evaluating the long-term effectiveness and impact of pneumococcal vaccination on serotypes reduction.
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Introduction
Streptococcus pneumoniae (pneumococcus) remains a major cause of
serious bacterial infection worldwide, especially in infants living in
developing regions [1,2].
Children are the major reservoir of this pathogen. Pneumococ-
cal carriage is highest during the first two years of life, and its
frequency varies according to geographic location and socioeco-
nomic pattern [3,4]. Individual nasopharyngeal (NP) carriage or
colonization is a prerequisite for pneumococcal disease and the
only source of transmission [5].
Pneumococcal conjugate vaccines (PCV) have been available
for over a decade but only recently were introduced into national
immunization programs of developing countries. The first
conjugate vaccinate available was 7-valent PCV (PCV7), which
offered protection against 7 serotypes (4, 6B, 9V, 14, 18C, 19F,
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23F). In 2010, PCV10 (including all serotypes in PCV7 plus 1, 5,
7F) was made available and PCV7 was replaced by PCV13
(including all serotypes in PCV10 plus 3, 6A, and 19A) [6–8].
Several studies have reported the effectiveness of PCV vaccines
in reducing both invasive and non-invasive disease in children and
adults [9–12]. Following PCV7 introduction, a reduction in
pneumococcal carriage of PCV7 serotypes was described, as well
as an increase in colonization by non-PCV7 serotypes [13,14].
Evidence has indicated that overall pneumococcal carriage rates
are unaltered after a period of PCV7 introduction, since decreases
in vaccine serotypes are counteracted by increases in carriage of
certain non-vaccine serotypes [14–19].
In 2010, PCV10 was introduced into Brazil’s National
Immunization Program (NIP), with universal access for all
children [20]. The early impact of vaccination on the reduction
of pneumonia hospitalization in children in Brazil was recently
reported [21]; however, the effectiveness of PCV10 on nasopha-
ryngeal carriage has not yet been evaluated. Data describing the
impact of PCV10 vaccination on carriage are scarce and to date
no significant effects of PCV10 on carriage have been described
[22,23].
Although pneumococcal diseases are found in every age group
[24], the primary reservoir of pneumococcus are children under
five years old [2]; because of that, the effect of PCV10 vaccination
on pediatric carriage and serotype distribution is critical.
The effect of PCV vaccination on carriage is of interest, since it
could play a significant role in the overall vaccine impact on
morbidity and mortality through minimizing vaccine serotype
transmission to the non-vaccinated population.
Assessing PCV effect on carriage is not an easy task. Most
studies have taken advantage of clinical trials to assess pneumo-
coccal colonization as an outcome of interest. After vaccine
introduction, one of the proposed methods to assess vaccine
effectiveness on pneumococcal carriage is repeated sampling of the
same individuals over time, which is expensive and invasive [24].
Recently, a cross- sectional study design was proposed to estimate
vaccine effectiveness on carriage [24].
With the aim of assessing the direct effectiveness of PCV10 on
pneumococcal carriage vaccine types, we conducted a cross-
sectional study, during the first year of vaccination. We also
investigated whether there was any difference of vaccine effective-
ness between the different dosing schedules used in Brazil’s NIP
during PCV10 introduction.
Methods
Study Design
A cross-sectional population-based household survey was
conducted. We measured PCV10 vaccination effect by comparing
vaccinated and unvaccinated individuals, all of whom are covered
by the same voluntary vaccination program [25,26]. The main
outcome of interest was pneumococcal vaccine serotype carriage
in children. The critical parameter of interest was PCV10 uptake
assessing as vaccine doses. Prevalence of pneumococcal carriage
was estimated. Children with carriage of vaccine serotypes
(‘‘cases’’) were compared with children that were negative for
pneumococcal carriage (‘‘non-cases’’). Non-vaccine serotype plus
non-pneumococcal carriage were combined within the same
category.
Study Location
The study was conducted in Goiania Municipality (,1,300 000
inhabs) in the Central West region of Brazil. Goiania is a highly
urbanized municipality in Brazil, where there is a high rate of
pneumococcal carriage and high vaccination coverage in infants
[27]. The study period was from December/2010 to February/
2011.
Schedules Recommended by the Brazilian Immunization
Program
PCV10 was made available free of charge to all children in
Brazil through its introduction into the Public Healthcare System
(Sistema U´nico de Sau´de, SUS) during March to October of 2010 in
all municipalities. Prior to that, PCV7 was available by the private
healthcare system. In addition, SUS provided the vaccine for
selected high risk individuals through its special immunization
activities [20].
Three different schedules were used during PCV10 introduction
in Brazil [20]:
N 3p+1: 3 primary doses for children between 6 weeks and 6
months of age (#6 m), with an interval of two months between
doses (minimum of 4 weeks) and a booster dose 6 months after
the third dose.
N 2p+1 (catch-up): a schedule of two doses for children aged 7–
11 months (7–11 m), with an interval of two months between
doses (minimum of 4 weeks) plus a booster dose six months
after the second dose.
N One single dose (catch-up): one dose for children aged 12–23
months (12–23 m).
For the country as a whole, the estimated vaccine coverage of a
complete 3-dose series during the first year of the vaccine
introduction was approximately 90% [28].
PCV10 Introduction and Schedules Evaluated at the
Present Study
PCV10 vaccine was introduced in Goiania Municipality in June
14th, 2010. The present study was conducted early during the first
year of PCV10 introduction as routine immunization. The
following PCV10 schedules were evaluated: 3p+0 (for children
aged #6 m); 2p+0 (for children aged 7–11 m); and one catch-up
dose (for children aged 12–23 m). Booster dose schedules (3p+1
and 2p+1) were not evaluated as the time period from vaccine
introduction and case enrollment was short (6–8 months) and
children enrolled did not have the opportunity to have been
exposed to the booster dose.
Study Population and Sample
For recruitment, the study targeted children of two age-groups:
7–11 months (7–11 m) and 15–18 months (15–18 m). The
rationale behind that choice was to assess vaccine effectiveness
considering the primary dose series as well as catch-up schedules
used by NIP during the vaccine introduction period.
A list of all children aged 7–11 m and 15–18 m resident in
Goiania Municipality was obtained from the National Information
System of Live Births with information on each child’s gender,
date of birth, address, and mother’s name. That list was sorted by
gender, district of residence (as obtained with the address) and age.
A systematic sampling process was put in place, so that a
proportional stratified random sample of children was obtained.
Sampled children were assessed through home visits.
Sample size was estimated at 1,287 considering a cross-sectional
design and estimated percentage of pneumococcal carriage among
non-vaccinated children of 58%. For the analysis of effectiveness,
this sample size would provide the study with a power of 80% to
detect as statistically significant (at the 5% level) a relative risk of
PCV10 Effect on Pneumococcal Carriage in Brazil
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0.67 or more for a range of frequency of exposure among controls
from 20% to 70% [29,30]. Prevalence of pneumococcal carriage
was obtained from a previous survey conducted in Goiania [27].
We estimated that about 65% would meet the study’s eligibility
criteria; therefore a total of 1,906 children were initially sampled.
Estimated relative risk was calculated considering data reported
from PCV clinical trial among children 9 months of age [31].
Inclusion and Exclusion Criteria
Sampled children were eligible to participate in the study if they
lived in Goiania, had no prior antibiotic use during the previous
seven days, and whose parent or legal guardian approved their
child’s participation in the study with supplied informed consent
signature.
Exclusion criteria included absence of the child’s parent or legal
guardian during the home visit, lack of vaccination card, failure to
collect NP swabs, and receipt of pneumococcal vaccines from
different manufacturers.
Ethical Considerations
Written informed consent was obtained by the child’s legal
parents/legal guardians. The protocol was approved by the Ethics
Committee of the Federal University of Goias (protocol #145/
2010).
Data Collection
During home visits, a standardized questionnaire was admin-
istered to legal guardians of all children included in the study. Data
on sociodemographic characteristics and factors potentially
associated with PCV10 effectiveness on vaccine-type carriage
such as day-care attendance, number of children living in the same
household, mother’s schooling, and access to private health
insurance were collected. PCV10 vaccination dates were obtained
from vaccination cards. For 9.1% of children, vaccination cards
were not available. Thus, vaccination dates were obtained from
Goiania’s Vaccination Online Database managed by the Munic-
ipal Data Processing Company, which is a comprehensive
database, with high completeness, and updated on time by
vaccination workers at the moment of vaccine administration in
vaccination services.
Nasopharyngeal Specimen Collection
Nasopharyngeal (NP) swabs were collected from all children
included in the study by trained research assistants during home
visits. Children were swabbed only once. Specimens were collected
with flexible perinasal calcium alginate swabs (Fisherbrand, Fisher
Scientific, Pittsburg, PA), which were placed into eppendorf tubes
containing skim milk/tryptone/glucose/glycerol (STGG) trans-
port medium [3]. The wired portion of the swab was cut at the top
level of the tube, allowing the calcium alginate portion of the swab
to drop into the vial. The samples were sent immediately after
collection to the Bacteriology Laboratory of the Federal University
of Goias, Brazil, vortexed to disperse the organisms from the swab,
and frozen at 280uC.
Specimen Processing
Cultures for S. pneumoniae were performed for all STGG
samples. The frozen vials containing the NP swabs in STGG
were thawed at room temperature and then vigorously vortexed
for 20–30 s. A 200 uL aliquot was inoculated into 6 ml of THY
broth (5 ml Todd-Hewitt broth with 0.5% yeast extract plus 1 mL
of rabbit serum) for enrichment culture and incubated for 6 h at
37uC in a 5% CO2 incubator for conventional culture on a blood
agar plate [32]. Alpha hemolytic colonies were tested for optochin
susceptibility and bile solubility. Colonies with different morphol-
ogies from each sample were analyzed separately. Pneumococci
confirmed isolates were frozen and sent to the Streptococcus
Laboratory, Centers for Disease Control and Prevention (CDC)
for serotyping by Quellung reaction with CDC-prepared antisera.
Non-typeable (NT) pneumococci isolates were tested for the
presence of 40 different capsular biosynthetic loci by conventional
multiplex PCR (cmPCR), with 8 sequential, that identify a total of
22 serotypes and 18 small serogroups (see http://www.cdc.gov/
ncidod/biotech/strep/pcr.htm for latest updates), as previously
described [32].
Definitions
Age-groups at 1st PCV10 dose: we used the date of birth and the
date at enrollment to assign children to each age-group. Children
ages were retrospectively calculated based on the date of the first
received PCV10 dose. For unvaccinated children, ages were
retrospectively calculated based on the date of PCV10 introduc-
tion in Goiania Municipality (June, 14th, 2010). Children were
then accordingly classified into three age-groups: #6 m; 7–11 m
and 12–18 m, since each age-group had a different recommended
number of doses (3p; 2p and one single catch-up), during the first
year of PCV10 introduction.
PCV10 dosing schedules: Children were categorized according to
the age-group at 1st PCV10 dose and number of doses
administered:
a) Unvaccinated: Children who did not receive any dose or
those who received only one dose before 12 months of age
(for which, there was a recommendation of two or three
doses). The rationale behind this assumption based on results
of efficacy trials in Hib vaccine on carriage which showed
that high serum anti-capsular type are needed for prevention
of mucosal colonization [33].
b) 2p+0: children who received two doses at any time during the
first year of life;
c) 3p+0: children who received three doses at any time during
the first year of life;
d) One catch-up dose: children who received one dose at or
after 12 months of age.
In order to differentiate the booster dose from primary doses,
we estimated the interval between doses; any dose administered
with an interval of at least 6 months was considered a booster dose.
Pneumococcal carriage: children who had a positive NP swab
culture for S. pneumoniae. Children were classified into the following
pneumococcal carriage categories:
1) PCV10 serotype pneumococcal carriage (vaccine-type): chil-
dren who were culture-positive for any of the pneumococcal
serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, or 23F;
2) Non-vaccine serotype pneumococcal carriage (non-vaccine
type): children culture-positive for any serotype other than the
ones included in PCV10;
3) non-pneumococcal carriage: culture-negative for pneumococ-
ci (regardless of culture results for other bacteria).
Data analysis
Statistical analyses were performed using the STATA software,
version 12.0 (Stata Corp, College Station, TX). The distribution of
children according to age-group at recruitment and at 1st PCV10
dose was compared.
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Prevalence of pneumococcal carriage among children was
estimated considering number of children colonized by S.
pneumoniae in the numerator, and number of children surveyed
for whom NP swabs were collected and processed in the
denominator.
Pneumococcal serotypes identified by Quellung reaction were
described (including those present in PCV10 and PCV13
composition). The main outcome of interest (exposure variable)
was pneumococcal carriage of PCV10 vaccine type. Unvaccinated
and vaccinated groups were compared regarding the following
variables potentially associated with colonization: age-group (at
enrollment), gender, number of children living in the same
household, mother’s schooling, and day-care attendance.
Rate ratio (RR) for NP pneumococcal vaccine-type carriage,
and its respective 95% confidence interval, was estimated as the
ratio between the prevalence of vaccine-types carriage in children
exposed to different dosing schedules (2p+0; 3p+0; and one catch-
up dose), being unvaccinated children the reference group.
Children with missing isolate serotype results were excluded from
the analysis.
Confounding variables related with both, vaccine uptake and
the outcome of interest (vaccine-type carriage) were included into
the multiple regression model to estimate adjusted RR. Poisson
regression with robust variance estimator was fitted to adjust the
RR for confounding variables. For this investigation, variables
associated with crowding (day-care attendance, and number of
children in household), and mother’s schooling were identified as
confounder; in addition, age (continuous variable) was also entered
into the model.
PCV10 vaccine effectiveness (VE) on vaccine-type carriage was
calculated using the adjusted RR and defined as the percentage
reduction in the risk of pneumococcal vaccine-types in vaccinated
children as compared with unvaccinated children as follows
[24,34]:
VE~(1{RR) x 100:
VE was reported with 95% confidence intervals (95%CIs).
Statistical significance of VE was established if the lower limit of
the 95% CI around VE was greater than 0 (zero). Table 1 displays
the categories of interest used to assess the RR and VE on PCV10
vaccine-type carriage.
RRfor vaccine-types~(a=N1)=(c=N2):
Therefore, the vaccine effectiveness VE for vaccine-types can be
estimated as.
VE~((a=N1){(c=N2))=(a=N1)~1{(c xN1)=(a xN2):
Results
From 1,906 children whose households were visited, 1,287
(67.5%) met the inclusion criteria and were included in the study.
Among the 1,287 children enrolled, 707 (54.9%) were aged 7–
11 m and 678 (52.7%) were male. Dosing schedules included 404
children (31.4%) who received 3p+0; 372 (28.9%) received 2p+0;
291 (22.6%) received a single dose, and 220 (17.1%) were not
vaccinated. Seventy children (5.4%) attended day-care and 832
(64.6%) used the public health insurance exclusively.
The distribution of children between age-group at enrollment
and age-group at 1st PCV dose is displayed on Table 2. The
majority of children enrolled (53.7%) received the 1st dose of
PCV10 at the first semester of life.
A total of 528 children were positive by pneumococcal culture
yielding an overall prevalence of pneumococcal carriage of 41.0%
(95% CI: 38.4%–43.7%). Prevalence of pneumococcal carriage for
children aged 7–11 m and 15–18 m was 41.7% and 40.2%,
respectively (p = 0.573). Of the 528 pneumococcal isolates, 494
(93.6%) were tested by Quellung reaction. Of these, 179 (36.2%)
carried PCV10 vaccine-types.
Overall, 35 serotypes were identified among the 494 isolates
tested, with the proportions of serotypes covered by PCV10 and
PCV13 estimated at 36.2% and 53.0%, respectively. As seen in
Figure 1, vaccine serotypes 6B (11.6%), 23F (7.8%), 14 (6.8%) and
19F (6.6%) were the most frequently observed, whereas PCV10
non-vaccine serotypes 6A (9.8%) and 19A (6.3%) were found in
slightly higher proportions compared to 6C (5.9%), 35B (4.3%),
11A (4.3%) and 15C (3.3%). Thirty-four (6.6%) pneumococcal
isolates could not be retrieved for serotyping. Simultaneous
colonization with at least two pneumococcal serotypes was found
in 17 (3.3%) children, six of which had a NT pneumococcal strain
identified. Sixty (11.4%) of the non-serotypeable isolates were
negative for capsular biosynthetic loci (positive cpsA control as well
as serotype-specific cps loci) corresponding to 40 serotypes or small
serogroups. NT isolates (by both culture and by cmPCR) were
observed in a higher proportion from children aged 15–18 months
(59.4%) compared with children aged 7–11 months (40.6%)
(p = 0.015). Serotypes 1, 5 and 7F were not detected.
The characteristics of 1,287 children according to vaccination
status are shown in Table 3. Unvaccinated and vaccinated groups
Table 1. Categories of exposure and outcome of interest considered for the estimation of rate ratio and vaccine effectiveness.
PCV10 dosing schedule Pneumococcal carriage Non-pneumococcal carriage{ Total of children surveyed
PCV10 vaccine-type Non-vaccine type
Vaccinated (3p+0, 2p+0, one catch-up dose1) a b N1– (a+b) N1
Unvaccinated c d N2– (c+d) N2
1Administered only for children 12 months of age or older.
{No culture for any other bacteria.
a+b+c+d = number of pneumococcal carriage, vaccine type and non-vaccine type.
c+d = number of unvaccinated children with pneumococcal carriage.
a+b = number of vaccinated children with pneumococcal carriage.
doi:10.1371/journal.pone.0098128.t001
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differed (p,0.05) in relation to number of children in household,
mother’s schooling, and pneumococcal nasopharyngeal carriage.
According to Table 4, there was a significant reduction of rate
ratio from unvaccinated children to those who received 3p+0
dosing schedule for pneumococcal nasopharyngeal vaccine-type
carriage (x2 for trend = 5.08; p = 0.024).
Table 5 shows the results of PCV10 effectiveness for pneumo-
coccal carriage vaccine-types in a multiple regression model. After
adjustment for confounders, children who had received 2p+0 or
3p+0 dosing schedules presented a significant reduction in
pneumococcal vaccine-type carriage, with PCV10 effectiveness
equal to 35.9% (p = 0.030) and 44.0% (p = 0.008), respectively,
when compared with unvaccinated children. In contrast, for
children who received one catch-up dose, no significant reduction
in vaccine-types was detected (p = 0.905).
Discussion
To the best of our knowledge, data describing the impact of
PCV10 on carriage after its introduction in routine schedule of
NIPs has not yet been reported. Brazil was the only country that
used multiple schedules during the period of PCV10 introduction,
with and without booster doses. Therefore, in this study, we were
able to evaluate different dosing schedules before the administra-
tion of the booster dose (2p+0 and 3p+0, and also one catch-up
dose). Hence, this investigation represented a unique opportunity
to gather evidence of PCV10 effectiveness during a transition
period, in which several dosing schedules were used for different
age-groups, some of which were not used nor are currently being
used by other countries.
The present study adds to the body of evidence describing
PCV10 effects on NP carriage following different dosing schedules.
Our data indicate that the primary series of either 3p+0 or 2p+0
dosing are effective in reducing PCV10 vaccine-type carriage. The
overall vaccine uptake in Goiania reached high rates during the
Table 2. Distribution of children within age-groups according to age at enrollment and age at first dose, Goiania, Dec/2010 Feb/
2011.
Age-group at 1st PCV10 dose1 Age-group at enrollment
`
Total n (%)
7–11 m n (%) 15–18 m n (%)
#6 m 662 (93.6) 29 (5.0) 691 (53.7)
7–11 m 45 (6.4) 240 (41.4) 285 (22.1)
12–18 m 0 311 (53.6) 311 (24.2)
Total 707 (100.0) 580 (100.0) 1287 (100.0)
`That is, the age-group at the moment of nasopharyngeal specimen collection.
1Unvaccinated children were classified according to age at PCV10 introduction into National Immunization Program.
doi:10.1371/journal.pone.0098128.t002
Figure 1. Distribution of pneumococcal serotypes carriage in children 7–18 months of age. Goiania, December/2010-February/
2011. Other serotypes: 9A, 9N, 10A, 15A, 17F, 18A, 20, 21, 22F, 23A, 23B, 24F, 25A, 28A, 29, 31, 33F, 34, 35F.
doi:10.1371/journal.pone.0098128.g001
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first 8 months of vaccination [28], which surely contributed to the
rapid reduction of vaccine-serotypes within the age-group targeted
by NIP for the primary schedules. Because no previous
observational study has evaluated the effectiveness of 3p+0 or
2p+0 PCV10 dosing schedules on pneumococcal carriage,
comparison of our findings is hampered. The majority of studies
assessing PCV7 effectiveness against pneumococcal carriage was
conducted at least 2 years after vaccine introduction. These studies
also did not consider the number of doses [13,14,17,18,35]. In
Colombia – Latin America, 2 years after PCV7 vaccination using
a 2p+1 dosing schedule, an important reduction on vaccine-type
carriage was observed among vaccinated children aged 12 to 18
months [36]. A recent systematic review of clinical trials assessing
pneumococcal NP carriage provided evidence of decreased
vaccine-type carriage for 2p+0, 2p+1, 3p+0 and 3p+1 schedules
compared with no vaccine uptake, with the reduction greatest for
the 3 primary dosing schedule [37].
As reported by other studies, we also observed a high prevalence
of NT carriage isolates [27,38,39]. In addition to Quellung
reaction for serotyping isolates, all NT pneumococci were tested
by cmPCR. Considering that NT pneumococci recovered from
carriage are often of non-encapsulated lineages, or can arise by
mutations within cps genes or reduced gene expression, molecular
tools are necessary for further characterization of NT strains
[40,41]. A considerable variety of serotype-specific cps loci were
identified (n = 35) within NT isolates, with cmPCR types 19A,
19F, and serogroup 6 (26.6%) accounting for a large percentage of
this isolate category (13% for 19A and 19F combined, 26.6% for
Table 3. Characteristics associated with unvaccinated and vaccinated children with PCV10.
Variables Unvaccinated
{ Vaccinated` p value
yes (%) no (%)
Pneumococcal nasopharyngeal colonization
Yes 113 (51.4) 415 (38.9) 0.001
No 107 (48.6) 652 (61.1)
Age-group at enrollment
7–11 months 114 (51.8) 593 (55.6) 0.308
15–18 months 106 (48.2) 474 (44.4)
Gender
Male 109 (49.5) 569 (53.5) 0.306
Female 111 (50.5) 498 (46.7)
No. of children,10 years old in household
$3 56 (25.6) 116 (10.9) ,0.001
#2 163 (74.4) 951 (89.1)
Mother’s schooling
#8 years 96 (43.8) 286 (26.9) ,0.001
.8 years 123 (56.2) 777 (73.1)
Day-care attendance
No 210 (95.5) 1006 (94.4) 0.519
Yes 10 (4.5) 60 (5.6)
Total 220 (17.1) 1067 (82.9)
{Defined as children who did not receive any dose at all (n = 96) or 1 dose before 12 months of age (n = 124).
`Defined as children who received 2 (n = 365) or 3 (n = 397) doses before 12 months of age or 1 cacth up dose .12 months of age (n = 291).
doi:10.1371/journal.pone.0098128.t003
Table 4. Rate ratio of PCV10 dosing schedule according to pneumococccal vaccine-type nasopharyngeal carriage.
PCV10 dosing schedules Nasopharyngeal carriage of PCV10 vaccine-type Total Rate Ratio (95%CI) p value
Yes No{
Unvaccinated 40 171 211 1.0
One catch-up dose1 44 239 283 0.820 (0.556; 1.210) 0.318
2p+0 46 320 366 0.663 (0.450; 0.978) 0.038
3p+0 49 344 393 0.658 (0.448; 0.964) 0.032
Total 179 1074 1253`
1Administered only for previously unvaccinated children who received the vaccine at 12 months of age or older.
{Includes non-vaccine type carriage and non-carriage children.
`34 isolates missing Quellung reaction results: unvaccinated (n = 9), one catch-up dose (n = 8), 2p+0 (n = 6), 3p+0 (n = 11).
doi:10.1371/journal.pone.0098128.t004
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serogroups 6A/6B and 6C/6D combined). A large number of
isolates belonging to serogroup 6 was identified (26.6%), as well as
serotypes 19A and 19F (13.0%). PCV13 cross-protection against
the non-vaccine serotype 6C is a possibility [42,43]. Considering
that serotypes 6A and 19A are included within PCV13, the use of
this vaccine could further decrease carriage of common disease-
causing serotypes.
Some limitations should be taken into account when interpret-
ing our results. Because this was an observational study, we
measured associations between PCV10 introduction and changes
in pneumococcal vaccine-type carriage. This does not reflect
causality, although data on potential confounding variables was
collected and considered in the analysis. We are also aware that
some unmeasured factors such as viral infections, seasonal
variations, vaccine coverage, and temporal trends could not be
taken into consideration, as it was a short-term cross-sectional
survey design. Nevertheless, cross-sectional studies of pneumococ-
cal carriage could be a feasible, rapid and timely approach, when
compared with follow-up studies for monitoring post-vaccination
effects on pneumococcal serotype distributions. This methodology
would be useful, mainly in settings where PCV has been recently
introduced and/or vaccination coverage have not reached high
rates [15,44,45].
Currently, the World Health Organization recommends the
administration of 2 catch-up PCV10 doses at an interval of at least
2 months to unvaccinated children aged 12–24 months at the time
of initial PCV10 vaccination [8]. Indeed, in our study, one single
catch-up dose was not effective in preventing vaccine-type carriage
for children 12 months or older. However, the possibility of
lacking power should be considered, as the analysis was stratified
by dosing schedule. This reduced the sample size, leading to a
wide 95%CI of PCV10 effectiveness, which might have not
allowed the detection of an eventual reduction in vaccine-type
carriage for this schedule.
Unfortunately, since data collection took place only once and
very early after vaccine introduction, there was not enough time to
enroll children who received the booster doses, thus, preventing
the assessment of 2p+1 and 3p+1 dosing schedule. Recent
evidence has shown that the administration of a booster dose
after two primary doses reduces pneumococcal spread from older
children to other members of the community [46]. Further cross-
sectional studies could further address this area.
In conclusion, we found that PCV10 was associated with high
protection against vaccine-type carriage with a 3p+0 and 2p+0
dosing schedules for children vaccinated before the first year of
life, soon after vaccine introduction into the routine immunization
schedule. Anticipating that further changes in serotype distribu-
tions in all ages is likely to occur as a consequence of continued
vaccination combined with herd effect, continued monitoring of
carriage serotype distributions is valuable for evaluating the long-
term effectiveness and impact of pneumococcal vaccination on
reducing vaccine serotypes and on emergence of non-vaccine
serotypes in Brazil.
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